CTMX · Healthcare · $592M
$2.72-1.09%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“CytomX의 핵심 항암제 'Varseta-M'이 대장암 환자에서 놀라운 효과를 보이고 있어요.”
In the company's words · 2026 1분기 earnings call